DK0689447T3 - Cytopatiske vira til behandling af og profylakse for neoplasia - Google Patents

Cytopatiske vira til behandling af og profylakse for neoplasia

Info

Publication number
DK0689447T3
DK0689447T3 DK94910177T DK94910177T DK0689447T3 DK 0689447 T3 DK0689447 T3 DK 0689447T3 DK 94910177 T DK94910177 T DK 94910177T DK 94910177 T DK94910177 T DK 94910177T DK 0689447 T3 DK0689447 T3 DK 0689447T3
Authority
DK
Denmark
Prior art keywords
replication phenotype
cells
neoplastic cells
viral
neoplastic
Prior art date
Application number
DK94910177T
Other languages
Danish (da)
English (en)
Inventor
Francis Mccormick
Original Assignee
Onyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Pharma Inc filed Critical Onyx Pharma Inc
Application granted granted Critical
Publication of DK0689447T3 publication Critical patent/DK0689447T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94910177T 1993-02-16 1994-02-16 Cytopatiske vira til behandling af og profylakse for neoplasia DK0689447T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1752593A 1993-02-16 1993-02-16
PCT/US1994/002049 WO1994018992A1 (en) 1993-02-16 1994-02-16 Cytopathic viruses for therapy and prophylaxis of neoplasia

Publications (1)

Publication Number Publication Date
DK0689447T3 true DK0689447T3 (da) 1999-10-18

Family

ID=21783090

Family Applications (2)

Application Number Title Priority Date Filing Date
DK94910177T DK0689447T3 (da) 1993-02-16 1994-02-16 Cytopatiske vira til behandling af og profylakse for neoplasia
DK98121753T DK0931830T3 (da) 1993-02-16 1994-02-16 Cytopatiske vira til terapi og profylakse af neoplasi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98121753T DK0931830T3 (da) 1993-02-16 1994-02-16 Cytopatiske vira til terapi og profylakse af neoplasi

Country Status (11)

Country Link
EP (2) EP0931830B1 (ja)
JP (2) JP3556666B2 (ja)
AT (2) ATE199568T1 (ja)
AU (1) AU682854B2 (ja)
CA (1) CA2152941C (ja)
DE (2) DE69426841T2 (ja)
DK (2) DK0689447T3 (ja)
ES (2) ES2157109T3 (ja)
GR (2) GR3030385T3 (ja)
PT (1) PT931830E (ja)
WO (1) WO1994018992A1 (ja)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0575518A1 (en) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5516631A (en) * 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
DK1314431T3 (da) 1993-04-30 2008-11-10 Wellstat Biologics Corp Oprensede sammensætninger af Newcastle disease virus
US5776743A (en) 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
JPH10509880A (ja) * 1994-11-28 1998-09-29 ジェネティック セラピー， インコーポレイテッド 組織特異的複製のためのベクター
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US6004942A (en) * 1995-08-30 1999-12-21 The Regents Of The University Of California Methods for treating arthritis by administering an apoptosis regulator
US6133243A (en) * 1996-02-22 2000-10-17 Onyx Pharmaceuticals, Inc. Liposomal-viral DNA complexes for treating disease
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
WO1998013508A1 (en) * 1996-09-24 1998-04-02 Dana-Farber Cancer Institute Method of targeting malignant cells using an e2f responsive promoter
EP0943004A2 (en) * 1996-11-18 1999-09-22 McGill University Post-mitotic neurons containing adenovirus vectors that modulate apoptosis and growth
US6080578A (en) * 1996-12-31 2000-06-27 Onyx Pharmaceuticals, Inc. Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
JP2002527455A (ja) * 1998-10-15 2002-08-27 カンジ，インコーポレイテッド 組換え欠失アデノウイルスベクター
WO2000022137A2 (en) * 1998-10-15 2000-04-20 Canji, Inc. Selectively replicating viral vectors
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US20020037274A1 (en) * 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
AU2145300A (en) * 1998-11-18 2000-06-05 Canji, Inc. Adenoviral vectors
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
EP1390046A4 (en) 1999-04-15 2005-04-20 Wellstat Biologics Corp TREATMENT OF NEOPLASMS WITH VIRUSES
DE19929569A1 (de) * 1999-06-21 2000-12-28 Holm Per Sonne Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1230378B1 (en) * 1999-11-15 2007-06-06 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
US7109029B2 (en) 2001-02-23 2006-09-19 Cell Genesys, Inc. Vector constructs
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
EP1944035A1 (en) 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Method for reducing pain using oncolytic viruses
AU2011221393A1 (en) * 2002-05-27 2011-09-29 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
US20060099178A1 (en) * 2002-05-27 2006-05-11 Holm Per S Novel use of adenoviruses and nucleic acids coding therefor
JP4988199B2 (ja) * 2002-10-15 2012-08-01 ホルム，ペル・ゾンネ 新規アデノウイルス、それをコードする核酸及びその使用
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
CA2532783C (en) 2003-07-21 2013-09-17 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
US20070110719A1 (en) * 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
KR100756055B1 (ko) 2006-01-27 2007-09-07 연세대학교 산학협력단 신생혈관 생성을 조절하는 재조합 아데노바이러스
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
BRPI1006179A2 (pt) 2009-01-13 2016-02-23 Transgène S A uso de uma fração de ácidos nucleicos mitocondriais, composição adjuvante, composição de vacina, e, kit da parte
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2012022496A2 (en) 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
KR20190138311A (ko) 2017-04-21 2019-12-12 베이롤 칼리지 오브 메드신 종양용해성 바이러스요법 및 면역요법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells

Also Published As

Publication number Publication date
DK0931830T3 (da) 2001-06-11
DE69417734D1 (de) 1999-05-12
EP0689447A4 (en) 1997-06-04
EP0689447A1 (en) 1996-01-03
JP2004115543A (ja) 2004-04-15
EP0689447B1 (en) 1999-04-07
DE69417734T2 (de) 1999-10-07
ATE199568T1 (de) 2001-03-15
JPH08507076A (ja) 1996-07-30
CA2152941C (en) 2003-04-22
GR3030385T3 (en) 1999-09-30
WO1994018992A1 (en) 1994-09-01
AU6272294A (en) 1994-09-14
ES2134346T3 (es) 1999-10-01
ATE178490T1 (de) 1999-04-15
GR3035914T3 (en) 2001-08-31
CA2152941A1 (en) 1994-09-01
DE69426841T2 (de) 2001-09-06
ES2157109T3 (es) 2001-08-01
AU682854B2 (en) 1997-10-23
EP0931830B1 (en) 2001-03-07
EP0931830A2 (en) 1999-07-28
PT931830E (pt) 2001-08-30
EP0931830A3 (en) 2000-07-12
DE69426841D1 (de) 2001-04-12
JP3556666B2 (ja) 2004-08-18

Similar Documents

Publication Publication Date Title
DK0689447T3 (da) Cytopatiske vira til behandling af og profylakse for neoplasia
DK0958371T3 (da) Cytopatiske vira til behandling og forebyggelse af neoplasi
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
DK1252323T3 (da) Virus-stammer til den onkolytiske behandling af cancer
NO20020571L (no) Peptider som blokkerer infeksjonsevnen, og fremgangsmåter for anvendelse av disse
ATE116637T1 (de) Sulfonische stilbenderivate zur behandlung von viruserkrankungen.
DE69133022D1 (de) Viral verursachte Zerstörung von Neoplastzellen
DE68906735D1 (de) Pharmazeutische zubereitung zur behandlung von viruskrankheiten mit leber-extrakt.
DK0652957T3 (da) Samlede viruspartikler og deres anvendelse i en vaccine imod rotaviral sygdom
NO953329D0 (no) Rekombinante viruser og deres anvendelse i genterapien for behandling av öyesykdommer
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
LV10384A (lv) Sastavs asins plazmas stabilizacijai pasterizacijas laika
DE69210737D1 (de) Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
ATE189604T1 (de) Extrakte von piliostigma thonningii, deren verwendung und diese enthaltende zubereitungen
AU630249B2 (en) Prevention of glycoprotein enveloped virus infectivity by quinolyloxazole-2-ones
FI893346A (fi) Icke-reverterande rna-virus.
UA6752C2 (uk) 4-(n-бензил) амінокарбоніл-1-метилпіридиній йодид-знеболюючий засіб з інтерфероногенними, протизапальними та жарознижуючими властивостями